Press release
Hyperlipidemia Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top players are Pfizer, AstraZeneca, Novartis, Arrowhead Pharmaceuticals, Esperion - The Lipid Management Company, Amgen, Eli Lilly a
Hyperlipidemia is unsuitable increase of cholesterol in blood, which can be inherited or acquired. Hypertriglyceridemia, and hypercholesterolemia are the two types of hyperlipidemia. Hyperlipidemia can be a result of various food products such as ice cream, cheese, red meat, and others. Furthermore, accumulation of cholesterol takes place even in arteries, which can result in high blood pressure. This can also result in clotting of blood, which may eventually lead to heart attack.Download the sample report at: https://www.pharmaproff.com/request-sample/1220
The diagnosis of the disorder can happen through blood tests to measure the level of cholesterol in blood. Exercise, weight loss, and healthy diet can better the situation. Hyperlipidemia can also be cured by medications, including nicotinic acid, statins, resins, cholesterol absorption inhibitors, fibrates, and others. Lipitor and Caduet (Pfizer Inc.), Crestor (AstraZeneca plc), Repatha (Amgen Inc.), and Vyotrin (Merck & Co. Inc.) are some of the U.S. Food and Drug Administration (USFDA) approved drug for the treatment of hyperlipidemia.
Get the detailed analysis at: https://www.pharmaproff.com/report/hyperlipidemia-therapeutics-pipeline-analysis
According to the research, many drugs being developed for hyperlipidemia are administered orally. It has been found that oral route of administration is non-invasive and easy to use, and ensures better effect for the disease.
There are several companies that are involved in developing therapeutics for hyperlipidemia have shown positive results of clinical trials. For instance, Esperion Therapeutics Inc. announced positive top-line result for final pivotal phase III trial of bempedoic acid. This can be very helpful in expanding the therapeutic regime for the disorder.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1220
Amgen Inc. and Arrowhead Pharmaceuticals Inc. collaborated in 2016 for RNAi ARC-LPA program, which was designed for the reduction of elevated lipoprotein which is a characteristic of hyperlipidemia. Like this, collaborations and acquisitions in the hyperlipidemia therapeutics market tend to contribute a lot in the development of hyperlipidemia therapeutics.
Lipitor, Vyotrin, Crestor, Caduet, and Repatha are some of the drugs used for the treatment of hyperlipidemia. These drugs hold significant share in the global hyperlipidemia market. Therefore, with the emergence of late- and mid-stage pipeline products, the overall hyperlipidemia therapeutics market is expected to grow significantly in the upcoming years.
Some of the key players involved in the development of hyperlipidemia therapeutics are Pfizer Inc., AstraZeneca plc, Novartis International AG, Amgen Inc., Arrowhead Pharmaceuticals Inc., Esperion Therapeutics Inc., Eli Lilly and Company, and Merck & Co. Inc.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperlipidemia Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top players are Pfizer, AstraZeneca, Novartis, Arrowhead Pharmaceuticals, Esperion - The Lipid Management Company, Amgen, Eli Lilly a here
News-ID: 1767898 • Views: …
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for Hyperlipidemia
Hyperlipidemia Drug Market Trends, Research Report, Growth, Opportunities, Forec …
The global hyperlipidemia drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the global hyperlipidemia market during the forecast period is the rapidly growing consumption of dairy products along with the sedentary lifestyle is fueling the market. Statins are the first line of treatment for hyperlipidemia. The expiration of patents of branded drugs will lead to the genericization…
Hyperlipidemia Drugs Market Size - Forecasts to 2026
As per the research conducted by GME, the Hyperlipidemia Drugs Market is estimated to be valued at USD 21.84 Billion in 2021 and is projected to reach USD 24.71 Billion by 2026 at a CAGR of 2.5%. increasing unusual cholesterol levels, upsurge in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) level cost-effective innovations, growing public awareness of nutraceuticals, increasing innovations in biotechnology, government initiatives, and increasing research and developments activities…
Global Hyperlipidemia Drug Market Size, Comprehensive Analysis & Forecast to 202 …
The global hyperlipidemia drug market is estimated to witness significant growth during the forecast period. The demand for a statin to manage cholesterol is driving the market growth across the globe. This drug supports lowering cholesterol, hence reduce the chances of cardiovascular diseases, stroke, and diabetes. Statins are used to manage the plaque on blood vessels and reduce the risk of blood clots. There are various statins options are available…
Hyperlipidemia Drugs Market - Operational challenges 2028 | Dr. Reddy's Laborato …
Global Hyperlipidemia Drugs Market: Overview
Hyperlipidemia is a technical term for abnormal amounts of fats (lipids) in the blood. The two noteworthy sorts of lipids found in the blood are triglycerides and cholesterol. Triglycerides are made when your body stores the additional calories it doesn't require for producing energy. They additionally come specifically from a man's eating routine in nourishments, for example, red meat and entire fat dairy. An eating regimen…
Hyperlipidemia Therapeutics Pipeline Review 2018 - Clinical Trials, Results, Des …
Hyperlipidemia refers to elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia). Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. The study analyzed that hyperlipidemia therapeutics pipeline comprises 53 drug candidates in different stages of development.
Explore report sample…
Hyperlipidemia Prescription Drugs Market To Witness Exponential Growth By 2019
Hyperlipidemia refers to abnormal elevation of lipids and/or lipoprotein levels. Risk factors associated with such condition include stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension and other cardiovascular diseases. Drugs which are used to treat hyperlipidemia act by either accelerating the elimination of lipoproteins from the body or decrease production of lipoproteins. These medications not only lower the unwanted cholesterol levels but also prove to be vital for lowering the…
